Online PR News – 22-January-2010 – – GlobalData has estimated the global Anti-Obesity Market to be valued at $1.4 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.7% for the next seven years to reach $3.1 billion by 2016. The increasing patient population and high unmet need in terms of safety and efficacy will be the primary drivers of this growth. However, safety concerns with the current anti-obesity drugs and low prescription rates will remain major challenges to sustain this growth.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Anti-Obesity-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData analyzed the current competition in the anti-obesity market and found it to be weak. Currently, there are only two prescription drugs available in the market, Roche’s Xenical (orlistat) and Abbott’s Meridia (sibutramine hydrochloride), of which Xenical lost its patent in December 2009. These drugs occupy two-thirds of the market in terms of revenues while generics and off-label indication drugs occupy the remaining third. These drugs belong to two different classes of drugs. Xenical is a lipase inhibitor, while Meridia is an appetite suppressant. There is another class of drug that produces therapeutic effect by enhancing the metabolism rate but it is made up from short-term treatment generic drugs. With current treatment options, patient satisfaction is low which provides ample opportunities for new entrants that can provide safer and more efficacious drugs.

GlobalData has analyzed that the contemporary medications in the global anti-obesity market have not been able to provide the desired safety and efficacy levels. There is a high unmet need in the current market as the drugs that are efficacious carry serious side effects, while the drugs that have demonstrated moderate safety profiles have not demonstrated equivalent efficacy. The generics available in the market have proved themselves efficacious only for short-term treatment and come with some serious side effects.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Anti-Obesity-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

A majority of medicines for obesity are appetite suppressants that act on central nervous system. Such medications have proven unsafe as they carry adverse psychiatric effects. The other class of drug, lipase inhibitors, has proven moderately efficacious with no serious side effects. Since lipase inhibitors provide a better solution to obesity management, they represent one promising category where more research could prove fruitful in meeting the current unmet needs of the market. In addition to these classes, there are medications that attempt to boost the body’s metabolism rate but they have proven moderately efficacious only as a short-term treatment. Therefore, high unmet need is expected to drive the anti-obesity market growth in the future.

GlobalData, the industry analysis specialist’s new report, “Anti-Obesity – Drug Pipeline Analysis and Market Forecasts to 2016”, is an essential source of information and analysis on the global anti-obesity market. The report identifies the key trends shaping and driving the global anti-obesity market. The report also provides insight on the prevalent competitive landscape and the emerging players. Most importantly, the report provides valuable insight on the pipeline products within the global anti-obesity market.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Anti-Obesity-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016